ABCC1 and lung carcinoma: For this purpose, Xu et al. [66] reported that drug efflux-mediated resistance in lung cancer cells could be effectively overcome by coating nanoparticles containing doxorubicin with cyclosporin A, which is a multimodal efflux pump inhibitor of both P-glycoprotein and MRP1 (ABCC1).